Evidence map›Paper›PMID 41274914›Full record

ArticleNPJ vaccines2025

Electroporation and LNP-mediated delivery of plasmid DNA-encoded H5N1 influenza virus hemagglutinin support protection against highly pathogenic avian influenza.

Ebony N Gary, Nicholas J Tursi, Casey E Hojecki, Robert Vendramelli, Martina Tomirotti, Bryce Warner, Cory Livingston, Thang Truong, Yangcheng Gao, Sachchidanand Tiwari and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ebony N GaryThe Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
Nicholas J TursiThe Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
Casey E HojeckiThe Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
Robert VendramelliNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Martina TomirottiThe Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
Bryce WarnerNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Cory LivingstonThe Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
Thang TruongNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Yangcheng GaoThe Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
Sachchidanand TiwariDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Norbert PardiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Darwyn KobasaNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
David B WeinerThe Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA. dweiner@wistar.org.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
NCI NIH HHS T32 CA009171NIAID NIH HHS 75N93019C00051NIH NCI CA009171
6 · The paper itself

Abstract

Highly pathogenic avian influenzas (HPAIs) is a continuing public health threat. Here, we describe the development of plasmid-encoded H5N1 hemagglutinin antigens representing clades that have caused human zoonoses. Electroporation (EP) delivery of clade 2.3.2.1c HA (pCamb) DNA was immunogenic in mice but only partially protective against clade 2.3.4.b challenge. Homologous challenge resulted in complete protection, suggesting that matched clade antigens are important for protection. Contemporary clade 2.3.4.4b HA (pMich) DNA plasmids supported robust cellular and humoral responses when delivered via EP. Co-immunization with plasmids representing both H5 clades supported high titers of binding and neutralizing antibodies against both antigens and complete protection from clade 2.3.4.4b challenge. We formulated the pMich plasmid DNA in lipid nanoparticles (LNPs). A single dose of pMich DNA-LNP supported long-lived immunity in mice that was protective against challenge at both acute and memory timepoints. These data demonstrate that DNA can support robust anti-HPAI immunity and protection.

Identifiers

PMID41274914
PMCPMC12727686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.